H.C. Wainwright Thinks Aptose Biosciences’ Stock is Going to Recover

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Aptose Biosciences (APTOResearch Report) today and set a price target of $12.00. The company’s shares closed last Tuesday at $0.71, close to its 52-week low of $0.71.

According to, Pantginis is ranked 0 out of 5 stars with an average return of -29.1% and a 21.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Bioline RX Ltd Sponsored ADR, Applied Genetic Technologies, and Lineage Cell Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aptose Biosciences with a $7.47 average price target.

See the top stocks recommended by analysts >>

Aptose Biosciences’ market cap is currently $66.71M and has a P/E ratio of -1.06.

Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of APTO in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.

Read More on APTO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More